Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Roth/MKM Reiterates Buy Rating on Replimune Group (REPL)
September 9, 2024 9:37 AM EDTRoth/MKM analyst Ben Paluch reiterated a Buy rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
The analyst comments "RP1 BLA Submission on Track for 2H24. We are incrementally positive on Replimune's announcement of a positive Pre-BLA Meeting with the FDA this morning. We continue to believe RP1 will get accelerated approval... More
